×
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
S&P 500   3,831.39 (+0.16%)
DOW   30,967.82 (-0.42%)
QQQ   286.98 (+1.72%)
AAPL   141.54 (+1.88%)
MSFT   262.90 (+1.28%)
META   168.25 (+5.14%)
GOOGL   2,264.66 (+4.13%)
AMZN   113.36 (+3.47%)
TSLA   701.50 (+2.89%)
NVDA   149.83 (+3.17%)
NIO   22.15 (+3.70%)
BABA   120.29 (+3.70%)
AMD   75.12 (+1.97%)
MU   56.73 (+5.74%)
CGC   2.71 (-3.56%)
T   21.10 (-0.99%)
GE   62.03 (-2.38%)
F   11.19 (-1.15%)
DIS   97.18 (+1.08%)
AMC   12.79 (-5.47%)
PFE   51.64 (-1.28%)
PYPL   74.36 (+4.15%)
NFLX   185.64 (+3.16%)
NASDAQ:GALT

Galectin Therapeutics Stock Forecast, Price & News

$1.50
+0.19 (+14.50%)
(As of 07/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.33
$1.54
50-Day Range
$1.19
$1.62
52-Week Range
$1.19
$4.40
Volume
5,445 shs
Average Volume
76,567 shs
Market Capitalization
$89.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
633.3% Upside
$11.00 Price Target
Short Interest
Bearish
6.45% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Galectin Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$15,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.75) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.06 out of 5 stars

Medical Sector

312th out of 1,428 stocks

Pharmaceutical Preparations Industry

147th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Galectin Therapeutics logo

About Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock News Headlines

Galectin Therapeutics GAAP EPS of -$0.17
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GALT
Employees
6
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/05/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+633.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-30,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.01 per share

Miscellaneous

Free Float
35,990,000
Market Cap
$89.09 million
Optionable
Optionable
Beta
1.55














Galectin Therapeutics Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Galectin Therapeutics stock.
View analyst ratings for Galectin Therapeutics
or view top-rated stocks.

What is Galectin Therapeutics' stock price forecast for 2022?

1 Wall Street analysts have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT stock forecasts range from $11.00 to $11.00. On average, they predict Galectin Therapeutics' stock price to reach $11.00 in the next year. This suggests a possible upside of 633.3% from the stock's current price.
View analysts' price targets for Galectin Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Galectin Therapeutics' stock performed in 2022?

Galectin Therapeutics' stock was trading at $2.07 at the beginning of the year. Since then, GALT shares have decreased by 27.5% and is now trading at $1.50.
View the best growth stocks for 2022 here
.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Galectin Therapeutics
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its earnings results on Monday, May, 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.07.
View Galectin Therapeutics' earnings history
.

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Mr. Joel Lewis, Pres, CEO & Director (Age 52, Pay $838.44k)
  • Mr. Jack W. Callicutt CPA, CPA, CFO, Treasurer & Sec. (Age 55)
  • Dr. Pol F. Boudes M.D., Ph.D., Chief Medical Officer (Age 65, Pay $688.56k)
  • Robert Tritt, Gen. Counsel
  • Ms. Beth Knowles, Exec. Assistant & Officer Mang.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $1.50.

How much money does Galectin Therapeutics make?

Galectin Therapeutics (NASDAQ:GALT) has a market capitalization of $89.09 million. The company earns $-30,530,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does Galectin Therapeutics have?

Galectin Therapeutics employs 6 workers across the globe.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The official website for Galectin Therapeutics is www.galectintherapeutics.com. The company can be reached via phone at (678) 620-3186, via email at ir@galectintherapeutics.com, or via fax at 770-864-1327.

This page (NASDAQ:GALT) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.